Search Results - "Brinck, Peter"

The Dog as a Second Species for Toxicology Testing Provides Value to Drug Development by Bower, Nancy, Achanzar, William E., Boulifard, Virginie, Brinck, Peter R., Kittel, Birgit, Vahle, John L.

“…The objective of the pharmaceutical industry is to develop new drugs that are safe for human use. In many cases, the accepted approach codified in guidance…”
Get full text

Evaluation of Cell Proliferation in Rat Mammary Glands Is Not Predictive of the Carcinogenic Potential of Insulin In Vivo by Jensen, Vivi Flou Hjorth, Brinck, Peter R., Nowak, Jette, Thorup, Inger, Sjögren, Ingrid, Mølck, Anne-Marie

“…For nonclinical safety-assessment of insulin analogues in vivo, mitogenic effects are compared to that of human insulin. Besides histopathologic evaluation,…”
Get full text

Generalized Cellular Hypertrophy is Induced by a Dual-Acting PPAR Agonist in Rat Urinary Bladder Urothelium In Vivo by Oleksiewicz, Martin B., Thorup, Inger, Nielsen, Henriette S., Andersen, Hanne V., Hegelund, Anne Charlotte, Iversen, Lars, Guldberg, Torben S., Brinck, Peter R., Sjogren, Ingrid, Thinggaard, Ulla K., Jørgensen, Lis, Jensen, Marianne B.

“…Some developmental dual-acting PPARα/γ agonists, such as ragaglitazar, have shown carcinogenic effects in the rodent urinary bladder urothelium after…”
Get full text

Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals by Harrell, Andrew W., Reid, Kirsty, Vahle, John, Brouta, Frederic, Beilmann, Mario, Young, Graeme, Beattie, Kylie A., Valentin, Jean Pierre, Shaid, Shajahan, Brinck, Peter

“…Following the European Commission decision to develop a roadmap to phase out animal testing and the signing of the US Modernisation Act, there is additional…”
Get full text

Toxicity of vitamin D analogues in rats fed diets with standard or low calcium contents by Mortensen, J T, Brinck, P, Binderup, L

“…Sprague-Dawley rats were fed either a standard diet with 0.9/0.7% Ca/P or a semisynthetic low-calcium diet with 0.5/0.4% Ca/P and treated orally for 28 days…”
Get more information